Oxford BioMedica plc OXB

In recent days, Veeva Systems has rolled out new AI-powered tools such as Veeva Study Builder Agent and Veeva Falcon Router, while announcing major customer wins including Oxford Biomedica adopting Veeva Quality Cloud and Amgen planning a global deployment of Veeva Vault CRM. Together, these developments highlight Veeva’s push to embed agentic AI across clinical, safety, quality, and commercial workflows, reinforcing its role as an end-to-end software partner for life sciences...

Oxford BioMedica PLC (OXBDF) posted GBP80.2 million in H1 2026 revenue, signed 17 new clients, and reaffirmed full-year guidance of GBP180-200 million despite a GBP7.6 million France site impairment.

Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Gene Transfer Technologies Market Size, Share & Trends Analysis - Global Opportunity Analysis and Industry Forecast (2026-2036)" has been added to ResearchAndMarkets.com's offering.The global Gene Transfer Technologies Market is projected to witness robust growth during the forecast period from 2026 to 2036, driven by the rapid expansion of gene and cell therapies, increasing investments in genomic medicine, and continuous advancements in vector engine

Oxford Biomedica (LON:OXB) reported higher first-half revenue and improved operating EBITDA as manufacturing activity increased, while management reiterated its full-year 2026 revenue guidance and longer-term growth targets. Revenue for the six months ended in 2026 rose 10% at constant currency to

Panmure Liberum has maintained its 'buy' rating on Oxford BioMedica PLC (LSE:OXB), the cell and gene therapy manufacturer, after its shares fell 15% following trial pauses by two of its customers. Novartis and Bristol Myers Squibb, both OXB customers, voluntarily paused enrolment in their...

Price targets for Oxford Biomedica have shifted, with examples including moves from 1,170 GBp to 1,140 GBp and then to 900 GBp, alongside new targets such as £9.00, £8.00, 595 GBp and 508 GBp. These changes align with a split analyst view, where some still back the long term potential and others focus more on execution risks and slower revenue conversion after recent results. As you read on, you will see how to track this evolving narrative and what to watch if you follow Oxford Biomedica...

OXB to demonstrate how its global, multi-vector CDMO platform is positioned to capture growth in the cell and gene therapy marketEvent to highlight OXB’s proven track record, leading technical capabilities, expanded international manufacturing network, deep regulatory expertise and strong client partnershipsSets out a vision for long-term growth, with an ambition to achieve revenues of c.£500m in 2030 and a clear path to sustainable profitability and cash flow generation Oxford, UK – 2 June 2026

The United Kingdom's stock market has recently faced challenges, with the FTSE 100 index slipping amid concerns over weak trade data from China, highlighting the interconnectedness of global economies. In such a climate, identifying stocks that are priced below their intrinsic value can present compelling opportunities for investors seeking to capitalize on potential long-term growth despite short-term market fluctuations.

The United Kingdom's stock market has recently experienced a downturn, with the FTSE 100 closing lower amid weak trade data from China, reflecting broader global economic challenges. In such an environment, identifying undervalued stocks can be crucial for investors seeking opportunities; these are companies whose intrinsic value may exceed their current market price, potentially offering significant returns if market conditions improve.

Oxford Biomedica’s latest analyst update keeps the fair value reference steady at £8.43, with no change from the prior assessment. Supportive and cautious analysts alike are framing this unchanged figure around differing views on the underlying assumptions, from revenue growth and margins to how reliable that £8.43 anchor is over the long term. As you read on, you will see how this evolving narrative might influence the way you track the stock from here. Stay updated as the Fair Value for...

The UK stock market has been experiencing turbulence, with the FTSE 100 index closing lower due to weak trade data from China, highlighting global economic challenges. Amidst these fluctuations, identifying undervalued stocks can offer potential opportunities for investors looking to capitalize on discrepancies between a company's market price and its intrinsic value.

The United Kingdom's stock market, as reflected by the FTSE 100, has recently faced downward pressure due to weak trade data from China, highlighting the interconnectedness of global economies and their impact on domestic indices. In such a climate, identifying stocks that may be trading below their estimated fair value can present opportunities for investors seeking potential upside in undervalued assets amidst broader market challenges.

The UK stock market has recently faced challenges, with the FTSE 100 index experiencing declines due to weak trade data from China, highlighting the interconnectedness of global economies. Amid these conditions, identifying undervalued stocks becomes crucial as investors seek opportunities that could offer potential value despite broader market pressures.

The United Kingdom's stock market has been under pressure recently, with the FTSE 100 index experiencing declines due to weak trade data from China and falling commodity prices. As global economic uncertainties weigh on investor sentiment, identifying undervalued stocks becomes crucial for those looking to capitalize on potential market inefficiencies.

The United Kingdom's stock market, represented by the FTSE 100, has recently experienced declines due to weak trade data from China, highlighting the interconnectedness of global economies. Despite these challenges, investors may find opportunities in undervalued stocks that could be trading at significant discounts, offering potential value in an otherwise cautious market environment.

The United Kingdom's stock market has experienced recent fluctuations, with the FTSE 100 index closing lower amid concerns over weak trade data from China and its impact on commodity-dependent companies. In this environment of uncertainty, identifying undervalued stocks can present opportunities for investors seeking potential value plays.

Oxford, UK – 8 May 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces its participation in the 30th Annual Meeting of the American Society of Cell and Gene Therapy (ASGCT), taking place from 11-15 May in Boston. OXB will exhibit at Booth #1331, where its commercial team will be available to discuss how OXB supports the development and manufacture of cell and gene therapies from pre-clinical through to commercialisation. Representing OXB onsite w

As the UK market grapples with global economic uncertainties, notably influenced by China's sluggish recovery and its impact on commodity-linked stocks, investors are keenly observing the performance of major indices like the FTSE 100 and FTSE 250. In such a volatile environment, identifying undervalued stocks can offer opportunities for those seeking potential value investments; Advanced Medical Solutions Group and two other UK companies may currently be trading below their estimated value.

Oxford BioMedica PLC (OXBDF) reports a 33% revenue increase and achieves profitability, while expanding its US commercial capabilities with a new facility acquisition.